Stem Cell Clinic

BioAge Labs Announces Pricing of Upsized Initial Public Offering

By Global News Feed

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share. All of the shares are being offered by BioAge. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $198.0 million.

Read more from the original source:
BioAge Labs Announces Pricing of Upsized Initial Public Offering

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

By Global News Feed

CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.

More:
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases

By Global News Feed

Gda?sk, Poland – 26 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has launched a study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. Data from the study are anticipated by March 30, 2025, and will help determine the pathway to clinical evaluation. The study will measure safety and efficacy of the CAR-Treg cell therapy, which will be administered systemically as well as intrathecally. PolTREG’s CAR-Treg cells are manufactured using the same technology platform as its lead product PTG-007, a polyclonal Treg cell therapy, for which PolTREG has gathered over a decade of clinical safety and efficacy data, largely in type-1 diabetes (T1D) patients.

Go here to read the rest:
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases

Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related…

By Global News Feed

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that the SAGA study of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) demonstrated a reduction of 0.25 sqmm/year vs. placebo (p=0.07) in the primary endpoint of GA lesion growth rate at 24 months. Gildeuretinol demonstrated a statistically significant reduction in the loss of low luminance visual acuity (LLVA) at 24 months (p=0.03). Gildeuretinol showed a favorable safety profile consistent with other studies of gildeuretinol in Stargardt disease. The topline results will be presented as a late breaker at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) during Retina Subspecialty Day on Friday, October 18, in Chicago.

See more here:
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related...

→←